Viking Therapeutics (VKTX) news
Recent news
Viking shares close down 7.7% for worst drop since April 2025
Viking Therapeutics (NASDAQ: VKTX) shares closed down 7.7% on August 14, marking the largest single-day decline since April 2025. The drop comes amid ongoing investor concerns over the company’s financial runway and upcoming capital-raising efforts. In July, the stock fell 18.6% overall, driven by…
AInvest Wire · Aug 14, 2026Viking Therapeutics appoints Dorothy Gemmell to board of directors
AInvest Wire · Jul 23, 2026Viking Therapeutics - to initiate Phase 3 trial of oral VK2735 later this year
AInvest Wire · Jun 24, 2026Viking Therapeutics - expects to report VK2735 dosing study results in 3Q26
Viking Therapeutics, Inc. (Nasdaq: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company is currently evaluating VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent…
AInvest Wire · Jun 24, 2026Viking Therapeutics announces appointment of Hubert C. Chen, M.D., as chief medical officer
AInvest Wire · Jun 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.